IPHA — Innate Pharma SA
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1598599 ·
France
Last close
$1.70
Market Cap
$189.89M
52W High
$2.71
52W Low
$1.17
ADV30
50,247
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 34,726,000 | 6,461,000 | 75,234,000 |
| Dec 2025 | — | — | — | — | 62,719,000 | 28,092,000 | 84,423,000 |
| Jun 2025 | — | — | — | — | 92,937,000 | 53,704,000 | 87,793,000 |
| Dec 2024 | — | — | — | — | 111,059,000 | 66,396,000 | 102,225,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-435,542,000
Inventory
—
Receivables
$7,610,000
ST Investments
$6,218,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$9,005,000
EBITDA
$-53,309,000
Free Cash Flow
$-34,073,624
Enterprise Value
$163,650,384
Total Cash
$34,310,000
Total Debt
$22,573,000
Shares Out
111,700,347
Trailing EPS
$-0.64
Book Value
$-0.27
ROE
—
ROA
-38.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,787,000 | -53,425,000 | -49,177,000 | 62,719,000 | 84,423,000 | -21,704,000 | -32,559,000 |
| Dec 2024 | 12,621,000 | -51,576,000 | -49,471,000 | 111,059,000 | 102,225,000 | 8,834,000 | -6,896,000 |
| Dec 2023 | 51,901,000 | -12,669,000 | -7,570,000 | 175,187,000 | 123,286,000 | 51,901,000 | -52,755,000 |
| Dec 2022 | 49,580,000 | -16,425,000 | -58,103,000 | 199,295,000 | 145,144,000 | 54,151,000 | -19,155,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.59
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TARA | Protara Therapeutics, Inc. | $193.83M | $3.28 | — |
| ACOG | Alpha Cognition Inc. | $184.46M | $8.47 | — |
| IPHYF | Innate Pharma SA | $184.31M | $1.65 | — |
| CRDL | Cardiol Therapeutics Inc. | $199.77M | $1.71 | — |
| CMPX | Compass Therapeutics, Inc. | $203.50M | $1.13 | — |
News headlines (Yahoo Finance, 1h cache)
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know
2026-09-23 16:00 · Yahoo
Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?
2026-09-23 00:40 · Yahoo
Innate Pharma Reports First Half 2026 Business Update and Financial Results
2026-09-17 05:00 · Yahoo
Sobi and Innate announce partnership is now effective following completion of closing conditions
2026-09-17 03:28 · Yahoo
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
2026-09-10 05:00 · Yahoo
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 05:00 · Yahoo
Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ...
2026-08-17 17:32 · Yahoo
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
2026-08-14 19:02 · Yahoo
Innate Pharma Announces Conference Call and Webcast
2026-08-14 09:30 · Yahoo
Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III
2026-08-10 12:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.